This minimally invasive, non-fusion therapy is designed to relieve chronic facet joint pain by restoring the articulating surface of the joint with a small implant while maintaining native anatomy and biomechanics.
The Glyder® Facet Restoration System is an investigational device and is intended exclusively for clinical investigations conducted within the EU. It has not been approved by the U.S. Food and Drug Administration for clinical investigation or marketing within the U.S.
→ Start of European Enrollment for the Glyder® (PDF)
→ Zyga completes enrollment in glissade clinical study (PDF)
Check back periodically for new information.